By otakuyassine3@gmail.com 
HCA Healthcare (NYSE:HCA – Get Free Report) had its target price lowered by analysts at Barclays from $392.00 to $366.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 17.12% from the stock’s previous close.
HCA has been the subject of a number of other reports. KeyCorp decreased their price objective on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $380.00 price objective on shares of HCA Healthcare in a research note on Tuesday, December 17th. StockNews.com lowered shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. TD Cowen lowered their target price on shares of HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research note on Monday, October 28th. Finally, Truist Financial lowered their price objective on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, January 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $383.53.
Get Our Latest Stock Report on HCA Healthcare
HCA Healthcare Stock Down 4.0 %
Shares of NYSE:HCA opened at $312.51 on Monday. The company has a market capitalization of $79.16 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. HCA Healthcare has a 52-week low of $279.93 and a 52-week high of $417.14. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. The company has a fifty day moving average of $313.49 and a 200-day moving average of $353.13.
HCA Healthcare (NYSE:HCA – Get Free Report) last released its quarterly earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter in the previous year, the company earned $5.90 EPS. On average, equities analysts predict that HCA Healthcare will post 21.75 EPS for the current fiscal year.
Insider Buying and Selling at HCA Healthcare
In related news, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Erol R. Akdamar sold 2,900 shares of HCA Healthcare stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the transaction, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Institutional Trading of HCA Healthcare
Hedge funds have recently bought and sold shares of the business. MML Investors Services LLC raised its stake in HCA Healthcare by 31.7% in the 3rd quarter. MML Investors Services LLC now owns 17,816 shares of the company’s stock valued at $7,241,000 after acquiring an additional 4,285 shares during the period. Meritage Group LP purchased a new stake in shares of HCA Healthcare during the 3rd quarter valued at approximately $150,548,000. Galvin Gaustad & Stein LLC purchased a new position in HCA Healthcare in the 4th quarter valued at approximately $18,044,000. Alpha DNA Investment Management LLC bought a new position in shares of HCA Healthcare in the third quarter worth $869,000. Finally, NRI Wealth Management LC bought a new stake in shares of HCA Healthcare during the 4th quarter valued at $2,896,000. 62.73% of the stock is currently owned by institutional investors.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
See Also
Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.